- Yahoo Finance
Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations
The Biden administration revealed the first 10 drugs that will face the Medicare negotiation process under the Inflation Reduction Act.
- Yahoo Finance
Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS
UBS believes there is little chance the lawsuits brought on by pharma companies will delay Medicare pricing negotiations.
- Benzinga
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as X-linked myotubular myopathy (XLMTM). Preclinical gene therapy candidate KT430 will seek to address XLMTM, a rare and life-threatening neuromuscular disease leading to severe muscle weakness, affecting predominantly males, with an incidence rate of approximately 1 in 40,000-50,000 newborn boys globally. The move comes after four deaths and
